New combo therapy takes on hard-to-treat skin cancer

NCT ID NCT03521830

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether the immunotherapy drug nivolumab, alone or combined with relatlimab or ipilimumab, can shrink tumors in people with advanced basal cell carcinoma that cannot be removed by surgery or has spread. About 57 participants will receive one of the drug combinations. The main goal is to see how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo), relatlimab, ipilimumab (Yervoy)
What this could lead to: If successful, this could offer new treatment options for people with advanced basal cell carcinoma that hasn't responded to other therapies.
What could go wrong: This is an early-phase trial with only 57 participants, so results may not apply to everyone. Immune-related side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA

Contacts and locations

Locations

Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.